.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Accenture
Baxter
Harvard Business School
McKesson
Citi
Chinese Patent Office
Merck
Farmers Insurance
Johnson and Johnson

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (San Mateo, CA), Kato; Darryl (San Francisco, CA), Kirschberg; Thorsten A. (Redwood City, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Mitchell; Michael L. (Castro Valley, CA), Parrish; Jay P. (El Dorado Hills, CA), Taylor; James (San Mateo, CA)
Assignee: Gilead Sciences, Inc. (Foster, CA)
Filing Date:Jun 07, 2012
Application Number:13/491,446
Claims:1. A compound of Formula I: ##STR01313## wherein each R.sup.1 is independently: ##STR01314## wherein R.sup.2 is: ##STR01315## wherein T.sup.1 is ##STR01316## or absent; wherein T.sup.2 ##STR01317## wherein L.sup.1 is a thienothiophene ring; wherein L.sup.2 is ##STR01318## or, ##STR01319## or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, further comprising a therapeutic agent selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

4. The pharmaceutical composition according to claim 3, further comprising a nucleoside analogue.

5. The pharmaceutical composition according to claim 4, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

6. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 1.

7. A compound selected from the group consisting of: ##STR01320## ##STR01321## or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 7 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, further comprising a therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

10. The pharmaceutical composition of claim 9, further comprising a nucleoside analogue.

11. The pharmaceutical composition of claim 10, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

12. A method for treating or preventing an HCV infection in a human, comprising administering to the human a compound of claim 7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Federal Trade Commission
Mallinckrodt
Cantor Fitzgerald
Merck
UBS
McKinsey
Daiichi Sankyo
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot